IL6 and congenital rubella syndrome: The i.t. expression of hPD-1 scFv by YST-OVH did not significantly increase the IFN-γ and IL-6 levels (p>0.05) detected in the serum on days 5 and 10 after treatment, showing no toxicity associated with cytokine release syndrome (CRS).